Author:
Almohsen Shahd S.,Demicco Elizabeth G.
Publisher
Springer Science and Business Media LLC
Reference65 articles.
1. WHO Classification of Tumours Editorial Board (2022) WHO classification of tumours. Lyon (France): International Agency for Research on Cancer; 2022. 5th edn [Available from: https://tumourclassification.iarc.who.int/chapters/52
2. Thompson LD, Miettinen M, Wenig BM (2003) Sinonasal-type hemangiopericytoma: a clinicopathologic and immunophenotypic analysis of 104 cases showing perivascular myoid differentiation. Am J Surg Pathol 27(6):737–749. https://doi.org/10.1097/00000478-200306000-00004
3. Sangoi AR, Bishop JA (2020) Variability of CD34 expression in sinonasal glomangiopericytoma: a potential diagnostic pitfall. Head Neck Pathol 14(2):459–64. https://doi.org/10.1007/s12105-019-01063-9
4. Haller F, Bieg M, Moskalev EA, Barthelmeß S, Geddert H, Boltze C, Diessl N, Braumandl K, Brors B, Iro H, Hartmann A, Wiemann S, Agaimy A (2015) Recurrent mutations within the amino-terminal region of β-catenin are probable key molecular driver events in sinonasal hemangiopericytoma. Am J Pathol 185(2):563–571. https://doi.org/10.1016/j.ajpath.2014.10.019
5. Suzuki Y, Ichihara S, Kawasaki T, Yanai H, Kitagawa S, Shimoyama Y, Nakamura S, Nakaguro M (2018) β-catenin (CTNNB1) mutation and LEF1 expression in sinonasal glomangiopericytoma (sinonasal-type hemangiopericytoma). Virchows Archiv 473(2):235–239. https://doi.org/10.1007/s00428-018-2370-9